e-learning
resources
Munich 2014
Monday, 08.09.2014
Pulmonary hypertension in lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Non-invasive haemodynamic measurement to detect treatment response in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia
G. Keir, T. Corte, K. Dimopoulos, M. Gatzoulis, P. Marino, E. Renzoni, T. Maher, A. Wells, S. J. Wort (London, United Kingdom; Brisbane, Sydney, Australia)
Source:
International Congress 2014 – Pulmonary hypertension in lung disease
Session:
Pulmonary hypertension in lung disease
Session type:
Thematic Poster Session
Number:
2335
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Keir, T. Corte, K. Dimopoulos, M. Gatzoulis, P. Marino, E. Renzoni, T. Maher, A. Wells, S. J. Wort (London, United Kingdom; Brisbane, Sydney, Australia). Non-invasive haemodynamic measurement to detect treatment response in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Eur Respir J 2014; 44: Suppl. 58, 2335
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Relation between pulmonary arterial remodeling and parenchymal disease in severe COPD and interstitial lung disease patients
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Effect of pulmonary hemodynamics on the prognosis of patients with emphysematous COPD after LVRS
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Sildenafil inhibit dose-dependently profibrotic and remodelling effects of TGFbeta1 on pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Pulmonary artery dilation and increased lung density in systemic sclerosis
Source: International Congress 2015 – A more functional view of chest pathology
Year: 2015
The evolution of effort tolerance and body composition in patients with idiopathic pulmonary arterial hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Pulmonary hypertension in idiopathic pulmonary fibrosis: Utility of HRCT
Source: International Congress 2014 – COPD and PAH related imaging
Year: 2014
Pulmonary hemodynamics and lung function in patients with COPD and DPLD
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Acute hyperoxic challenge improves haemodynamics & Pulmonary vascular stiffness in interstitial lung disease-associated pulmonary hypertension
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Pulmonary hypertension in interstitial lung disease: Non-invasive assessment for detection and prognosis
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016
Sildenafil decreases the contractile response to serotonin (5HT) in pulmonary arteries from patients with idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH)
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Non-invasive cardiac output assessment in pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Exercise-induced pulmonary pressure changes in scleroderma patients – A follow-up study
Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange
Year: 2014
The incidence of chronic thromboembolic pulmonary hypertension secondary to acute pulmonary thromboembolism
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Characteristics of patients with pulmonary hypertension in end stage renal disease
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept